1 recently reported a 6.5% incidence of subsequent myelodysplastic syndrome or acute myelogenous leukemia (t-MDS/AML) in patients treated for APL.
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TO THE EDITOR Latagliata et al
1 recently reported a 6.5% incidence of subsequent myelodysplastic syndrome or acute myelogenous leukemia (t-MDS/AML) in patients treated for APL.
From 1980 to 2001, we treated 192 patients with newly diagnosed APL: 40% with chemotherapy without all-trans retinoic acid (ATRA), and 60% with ATRA ± chemotherapy. The median follow-up in the pre-ATRA group is 129 months (range 59 to 262), and 32 weeks (6 to 470 weeks) in the ATRA group. CR rate was 74%, 4% died during consolidation therapy, and 28% relapsed. Median disease-free survival was 278 weeks, and median overall survival was 195 weeks. Patients that have been in CR for more than 2 years can be called potentially cured (59 out 68 have not relapsed with a median followup of 4 years).
Two of these 68 potentially cured patients have developed t-MDS/AML. One has been previously reported, 2 and found to have t-MDS/AML 32 months after therapy for APL, and while still on first CR. The second was a 34-year-old female induced in 1994 with idarubicin 12 mg/m 2 /day × 4 and ATRA 45 mg/m 2 /day achieving CR 1 month later. Post-remission therapy consisted of two courses of idarubicin 12 mg/m 2 /day × 3 1 month apart, and three cycles of POMP (6-mecaptopurine, vincristine, methotrexate and prednisone), alternating with one cycle of idarubicin 12 mg/m 2 /day × 2 for a total of 18 months. In September 1996, cytogenetic analysis demonstrated a Leukemia (2002) 16, 1888-1889. doi:10.1038/sj.leu.2402627
Blastic variant of mantle cell lymphoma occurring in immunosuppressed patients

TO THE EDITOR
We read with interest the paper by Bernard et al 1 reporting 33 patients with the blastic variant of mantle cell lymphoma. We note that none of the cases was reported as occurring in patients who were immunosuppressed and would like to report two cases of the blastic variant of mantle cell lymphoma which were both associated with significant background immunosuppression.
A 40-year-old female presented to the neurosurgeons with a 2-week history of behavioral change, left-sided facial and arm weakness and confusion. A magnetic resonance imaging scan showed a 5 × 4 cm mass in the frontal lobe with midline shift.
She had been unwell for the previous year, with an episode of right lower lobe pneumonia, persistent cough, weight loss and hair thinning. A diagnosis of systemic lupus erythematosis had been made on the basis of postive anti-nuclear and anti-smooth muscle auto-antibodies and she had been on systemic steroid therapy for the previous 2 months. (17)(p11.2) without evidence of t(15;17). The marrow had 1% blasts, white blood cell count (WBC) was 6.8 × 10 9 /l, hemoglobin (hgb) 11.9 g/dl, and platelet count was 145 × 10 9 /l. In January 1997 further clonal abnormalities were found including hypodiploid metaphases ranging from 41 to 44 with del3(p23p25), −5, der(6)t(6;15)(p21;q15), −15, add 17(p13), the WBC was 22.3 × 10 9 /l, the hgb 7.8 g/dl, and the platelet count was 64 × 10 9 /l. Marrow aspiration revealed 8% blasts. The patient died 4 months after undergoing allogeneic bone marrow transplantation.
In summary, we have identified two patients with t-MDS/AML in a cohort of 68 (3%) that had duration of remission Ͼ24 months. These results are not significantly different to those reported by Latagliata et al.
1 In their series, three patients (4%) developed t-MDS/AML while in first CR, all of them more than 2 years after diagnosis. Although the incidence of t-MDS/AML is relatively low, it is an important potential threat to patients with a potentially curable disease. Craniotomy and excision of the tumour were performed. Histology of the tumour revealed diffuse infiltration with irregular lymphoid cells with prominent blastic morphology. Immunohistochemistry showed positivity with anti-CD20, CD79a, CD5, CD10, Epstein-Barr virus latent membrane protein 1 (LMP1) and nuclear positivity for cyclin D1. The histology was reviewed by our central review body the Scottish and Newcastle Lymphoma Group and was confirmed to be the blastic variant of mantle cell lymphoma. There was no evidence of any other sites of disease on CT scan or bone marrow examination and her LDH was within normal limits.
In view of her presentation with an aggressive primary CNS lymphoma she underwent HIV testing which was positive and her CD4 count was zero. Following neurosurgery she had a dense left hemiparesis. Her condition suddenly deteriorated with signs of raised intracranial pressure and she died prior to chemotherapy commencing.
A 50-year-old female with a 26-year history of Behcets retinal vasculitis was investigated for upper abdominal pain, symptoms of gastrooesophageal reflux and nausea. She had been on systemic steroids for over 20 years and azathioprine and cyclosporin A had been added 5 years previously because of deteriorating vision. Two years later the cyclosporin was changed to FK506 and she was registered blind.
Upper gastrointestinal endoscopy revealed a large ulcerating mass occupying most of the body of the stomach. Histology of this lesion showed a dense infiltrate of blastic and intermediate-sized lymphoid cells staining positively with anti-CD20, CD5, and nuclear positivity
